Associate Director, PBPK-PD Translational Modeling, DMPK

GSK

5d•Hybrid

About The Position

We have an exciting opportunity for a scientifically ambitious Associate Director to join the PBPK-PD Translational Modeling group within DMPK. The role focuses on developing and applying mechanistic PBPK-PD models for oligonucleotide therapeutics and antibody-drug conjugates, translating in vitro and preclinical data into predictions of tissue exposure, target engagement, and pharmacological effects in patients. Experience in T-cell and myeloid cell engager modelling is advantageous. You will provide PBPK-PD expertise to support target validation, modality selection, human dose prediction, and PK/PD strategies from early discovery through first-in-human studies. The role also involves integrating PBPK-PD, QSP, and AI-enabled modelling approaches to drive data-informed candidate selection and development decisions.

Requirements

PhD in pharmacokinetics, pharmaceutical sciences, chemical or biomedical engineering, systems pharmacology, applied mathematics, statistics or a closely related quantitative discipline.
Strong experience developing and applying mechanistic PBPK and/or PK-PD models in an industry or equivalent research setting, with verifiable proficiency in PBPK and systems modeling platforms (e.g. Simcyp, SimBiology/MATLAB, etc.).
Demonstrated experience delivering human PK and efficacious dose predictions and translational PK/PD assessments.
Demonstrated ability to apply AI/Tech-enabled modeling frameworks

Nice To Haves

Direct experience modeling oligonucleotide and antibody-drug conjugates or other bioconjugates
Track record of implementing MID3 approaches to accelerate progression of novel therapeutics and to strengthen the quality of portfolio decisions
Demonstrated aptitude for productive collaboration in a multi-disciplinary matrix team, with effective communication and personal accountability for timely delivery

Responsibilities

Translational PBPK-PD modeling for Biologic Modalities
Building, qualifying and applying mechanistic whole-body PBPK-PD models for siRNA, ASO and conjugated oligonucleotides
Building and applying ADC PBPK models integrating antibody disposition, target expression and internalization, DAR distribution and deconjugation, linker stability, payload release and intratumoral penetration including bystander effects
Delivering human efficacious dose projections — translating preclinical PK/PD into clinical dose, regimen and duration with explicit treatment of uncertainty and driving assumptions
Defining project-level PK/PD modeling strategies and articulating them to project teams and governance bodies
Creating opportunities to apply integrated PBPK-PD and QSP approaches earlier in discovery
Partnering with Discovery, Biology, Chemistry, Toxicology, Bioanalysis and Clinical Pharmacology to embed model-informed drug discovery and development (MID3) into the standard progression path and define quantitative candidate selection criteria
Applying AI/Tech-enabled modeling frameworks is essential to this role
Engaging line and middle management, project teams and external partners at functional, strategic and tactical level, and representing DMPK modeling at internal forums and project team meetings
Promoting external credibility through peer-reviewed publications and conference presentations.